Tradestie Institutional Equity Comparison Engine
SRZN vs OKUR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SRZN Overall Edge
SRZN Captures Institutional Edge (2โ1 Pillars ยท 4โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Momentum & Technical, Options & Structure while OKUR counters with relative strength in Growth & Margin. Fundamentally, SRZN trades at N/M Forward P/E with -485.4% operating margin (+408.6% YoY revenue) versus OKUR at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, SRZN sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro) against OKUR sits in SURGE (100th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
SRZN N/M vs OKUR N/M Fwd P/E
Growth & Margin Winner
OKUR
Op Margin -485.4% vs 0.0% ยท YoY +408.6% vs +0.0%
Momentum & Technical Winner
SRZN
1Y +110.8% vs -2.2% ยท 52W Pos 63% vs 20%
Options & Structure Winner
SRZN
CONSOLIDATION (13th %ile IV) vs SURGE (100th %ile IV)
SRZN
NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$28.46
-7.21% 1D
Market Cap
$642.7M
1M Return
+10.52%
1Y Return
+110.81%
Forward P/E
N/M
Unified AI Score
36.0 / 100
SELL
Tech 15.0
Fund 42.0
Flow 65.0
Mom 50.0
OKUR
NASDAQ
OnKure Therapeutics, Inc. Class A Common Stock
Pharmaceutical Preparations
$2.70
-2.17% 1D
Market Cap
$113.7M
1M Return
+4.65%
1Y Return
-2.17%
Forward P/E
N/M
Unified AI Score
36.0 / 100
SELL
Tech 20.0
Fund 46.0
Flow 64.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
SRZN +110.81%
OKUR -2.17%
Spread: +112.98 pp (SRZN Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
SRZN TTM Op. Margin: -485.4%
OKUR TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SRZN vs OKUR. Trailing 12-month operating profitability (SRZN -485.4% vs OKUR 0.0%) and valuation multiples (SRZN N/M vs OKUR N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SRZN | OKUR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $642.7M | $113.7M | Larger Scale | SRZN |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +408.6% | +0.0% | Higher Growth | SRZN |
| Operating Margin (TTM) Profitability | -485.4% | 0.0% | Higher Margin | OKUR |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -62.8% | -55.2% | Higher ROE | OKUR |
| 52-Week Range Position Momentum | 63% ($13โ$38) | 20% ($2โ$5) | Stronger Trend | SRZN |
| Beta / 30D Volatility Risk Regime | 1.29ฮฒ ยท 73% Vol | 0.96ฮฒ ยท 100% Vol | Lower Realized Risk | SRZN |
| Unified Institutional Score Composite Signal | 36.0 / 100 (SELL) | 36.0 / 100 (SELL) | Higher Composite | Tie |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full SRZN vs OKUR Buy Guide
SRZN
CONSOLIDATION
41d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
13th %ile
IV Regime
Compressed (<25th %ile)
OKUR
SURGE
8d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
100th %ile
IV Regime
Extreme (>80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither SRZN nor OKUR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.